Cognitive change in donepezil treated patients with vascular or mixed dementia

Canadian Journal of Neurological Sciences

Volumn 40, Issue 4, 2013, Pages 564-571

  Rockwood, Kenneth ^a   Mitnitski, Arnold ^a   Black, Sandra E ^b   Richard, Matthew ^a   Defoy, Isabelle ^c  

^a DALHOUSIE UNIVERSITY   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL;

AGED; ALZHEIMER DISEASE; ARTICLE; CAREGIVER; CLINICAL GLOBAL IMPRESSION SCALE; COGNITIVE DEFECT; CONSTRUCT VALIDITY; DEMOGRAPHY; DRUG DOSE INCREASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MIXED DEMENTIA; MULTIINFARCT DEMENTIA; NEUROPSYCHIATRY; OPEN STUDY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SAMPLE SIZE;

EID: 84879387084     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100014670     Document Type: Article

References (44)

1. Moorhouse P, Rockwood K. vascular cognitive impairment: Current concepts and clinical developments. lancet Neurol. 2008;7: 246-55 (Pubitemid 351215983)
2. Gorelick PB, Scuteri A, Black SE, et al. vascular contributions to cognitive impairment and dementia: A statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42: 2672-713
3. Román GC, Tatemichi TK, Erkinjuntti T, et al. vascular dementia: Diagnostic criteria for research studies. Report of the NINDSAIREN International Workshop. Neurology. 1993;43: 250-60 (Pubitemid 23060253)
4. Wang BW, lu E, Mackenzie IR, et al. Multiple pathologies are common in Alzheimer patients in clinical trials. Can J Neurol Sci. 2012;39(5).: 592-9.
5. Snowdon DA, Greiner lH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 1997;277: 813-7. (Pubitemid 27111317)
6. Neuropathology Group. Medical Research Council Cognitive Function and Aging Study. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). lancet. 2001;357: 169-75
7. launer lJ, Petrovitch H, Webster RG, Markesbery W, White lR. AD brain pathology: Vascular origins? Results from the HAAS autopsy study. Neurobiol Aging. 2008;29: 1587-90
8. Shi GX, liu CZ, Wang lP, Guan lP, li SQ. Biomarkers of oxidative stress in vascular dementia patients. Can J Neurol Sci. 2012;39(1).: 65-8.
9. Perry G, Phelix CF, Nunomura A, et al. Untangling the vascular web from Alzheimer disease and oxidative stress. Can J Neurol Sci. 2012;39(1).: 4.
10. Birks J. The evidence for the efficacy of cholinesterase inhibitors in the treatment of Alzheimer's disease is convincing. Int Psychogeriatr. 2008;20: 1-7.
11. Erkinjuntti T, Roman G, Gauthier S, Feldman H, Rockwood K. Emerging therapies for vascular dementia and vascular cognitive impairment. Stroke. 2004;35: 1010-17 (Pubitemid 38419819)
12. Wong Cl, Bansback N, lee PE, Anis AH. Cost-effectiveness: Cholinesterase inhibitors and memantine in vascular dementia. Can J Neurol Sci. 2009;36(6).: 735-9.
13. Wilkinson D, Doody R, Helme R, et al. Donepezil in vascular dementia: A randomized, placebo-controlled study. Neurology. 2003;61: 479-86 (Pubitemid 37025364)
14. Black S, Román GC, Geldmacher DS, et al. Donepezil 307 vascular Dementia Study Group. Efficacy and tolerability of donepezil in vascular dementia: Positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke. 2003;34: 2323-30 (Pubitemid 37221934)
15. Mohs RC, Knopman D, Petersen RC, et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: Additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11(SUPPL2).: S13-21
16. Román GC, Salloway S, Black SE, et al. Randomized, placebocontrolled, clinical trial of donepezil in vascular dementia: Differential effects by hippocampal size. Stroke. 2010;41: 1213-21
17. Gauthier S, Patterson C, Chertkow H, et al. Recommendations of the 4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD4). Can Geriatr J. 2012 Dec; 15(4).: 120-6.
18. levine DA, langa KM. vascular cognitive impairment: Disease mechanisms and therapeutic implications. Neurotherapeutics. 2011;8: 361-73
19. Gauthier S, Ferris S. Outcome measures for probable vascular dementia and Alzheimer's disease with cerebrovascular disease. Int J Clin Pract Suppl. 2001;(120).: 29-39
20. Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology. 2001;57: 489-95 (Pubitemid 32757598)
21. Román GC, Wilkinson DG, Doody RS, Black SE, Salloway SP, Schindler RJ. Donepezil in vascular dementia: Combined analysis of two large-scale clinical trials. Dement Geriatr Cogn Disord. 2005;20: 338-44 (Pubitemid 41642791)
22. American Psychiatric Association. Diagnostic and Statistical Manual. 4th ed., text rev. Washington: American Psychiatric Association; 2005
23. Hachinski vC, Iliff lD, Zilhka E, et al. Cerebral blood flow in dementia. Arch Neurol. 1975;32: 632-7.
24. Reisberg B. Functional assessment staging (FAST). Psychopharmacol Bull. 1988;24: 653-9.
25. Rockwood K, Black SE, Song X, et al. Clinical and radiographic subtypes of vascular cognitive impairment in a clinic-based cohort study. J Neurol Sci. 2006;240(1-2).: 7-14 (Pubitemid 41814947)
26. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23: 56-62
27. Molloy DW, Standish TI. A guide to the standardized Mini-Mental State Examination. Int Psychogeriatr. 1997;9(SUPPL1).: 87-94; discussion 143-50 (Pubitemid 28045345)
28. Gélinas I, Gauthier l, McIntyre M, Gauthier S. Development of a functional measure for persons with Alzheimer's disease: The disability assessment for dementia. Am J Occup Ther. 1999 Sep- Oct;53(5).: 471-81
29. Royall DR, Cordes JA, Polk M. ClOX: An executive clock drawing task. J Neurol Neurosurg Psychiatry. 1998;64: 588-94 (Pubitemid 28204143)
30. Gladsjo JA, Schuman CC, Evans JD, Peavy GM, Miller SW, Heaton RK. Norms for letter and category fluency: Demographic corrections for age, education, and ethnicity. Assessment. 1999; 147-78
31. Kaufer DI, Cummings Jl, Ketchel P, et al. validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci. 2000;12: 233-9. (Pubitemid 30303778)
32. Rockwood K. An individualized approach to tracking and treating Alzheimer's disease. Clin Pharmacol Ther. 2010;88: 446-9.
33. Molnar FJ, Man-Son-Hing M, Fergusson D. Systematic review of measures of clinical significance employed in randomized controlled trials of drugs for dementia. J Am Geriatr Soc. 2009; 57: 536-46
34. Molnar FJ, Man-Son-Hing M, Hutton B, Fergusson DA. Have lastobservation- carried-forward analyses caused us to favour more toxic dementia therapies over less toxic alternatives? A systematic review. Open Med. 2009;3(2).: E31-50
35. little RJ, D'Agostino R, Cohen Ml, et al. The prevention and treatment of missing data in clinical trials. N Engl J Med. 2012; 367(14).: 1355-60
36. liang MH, Fossel AH, larson MG. Comparisons of five health status instruments for orthopedic evaluation. Med Care. 1990; 28: 632-42
37. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Englewood Cliffs: Lawrence Erlbaum Associates; 1988
38. Rockwood K. Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2004;75(5).: 677-85 (Pubitemid 38526674)
39. Moorhouse P, Song X, Rockwood K, et al., Executive dysfunction in vascular cognitive impairment in the consortium to investigate vascular impairment of cognition study. J Neurol Sci. 2010;288: 142-6.
40. Rockwood K. Should we listen to people affected by dementia? CNS Neurosci Ther. 2011;17 (1).: 1-3.
41. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer's disease. lancet. 2011;377(9770).: 1019-31
42. Rockwood K, Black SE, Robillard A, lussier I. Potential treatment effects of donepezil not detected in Alzheimer's disease clinical trials: A physician survey. Int J Geriatr Psychiatry. 2004;19(10).: 954-60 (Pubitemid 39378290)
43. Behl P, lanctôt Kl, Streiner Dl, Black SE. The effect of cholinesterase inhibitors on decline in multiple functional domains in Alzheimer's disease: A two-year observational study in the Sunnybrook dementia cohort. Int Psychogeriatr. 2008;20: 1141-59
44. Gillette-Guyonnet S, Andrieu S, Nourhashemi F, et al. REAl.FR study group. long-term progression of Alzheimer's disease in patients under antidementia drugs. Alzheimers Dement. 2011;7 (6).: 579-92